An interesting post from:
http://antioxidant-scleroderma.blogspot.com/2010/02/localized-scleroderma-and-zinc-pilot.html
Eur J Dermatol. 2010 Feb 2 Esthetic or functional repercussions in localized scleroderma may be considerable. Numerous treatments have been proposed with limited effectiveness.
Source::
http://antioxidant-scleroderma.blogspot.com/2010/02/thrombin-induced-ccn2-expression-as.html
Scleroderma (systemic sclerosis, SSc) is a fibrotic disease for which there is no therapy. CCN2 (connective tissue growth factor, CTGF) is a marker and mediator of fibrosis. Previously, it has been shown that thrombin induces CCN2 expression in fibroblasts
View original here:
http://antioxidant-scleroderma.blogspot.com/2010/02/natural-products-as-gold-mine-for.html
Arthritis , an inflammation of the joints, is usually a chronic disease that results from dysregulation of pro-inflammatory cytokines (e.g. tumour necrosis factor and interleukin-1?) and pro-inflammatory enzymes that mediate the production of prostaglandins (e.g
Here is the original:
http://antioxidant-scleroderma.blogspot.com/2010/02/oxidative-stress-and-glutathione-in-tgf.html
Abstract Transforming growth factor ? (TGF-?) is the most potent and ubiquitous profibrogenic cytokine, and its expression is increased in almost all the fibrotic diseases and in experimental fibrosis models.